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After tissue injury, ﬁbroblast migration from the peri-wound collagenous stroma into the ﬁbrin-laden wound is
critical for granulation tissue formation and subsequent healing. Recently we found that ﬁbroblast transmigration
from a collagen matrix into a ﬁbrin matrix required the presence of ﬁbronectin. Several integrinsa4b1, a5b1, and
avb3with known ﬁbronectin binding afﬁnity were necessary for this invasive migration. Here we examined another
family of cell surface receptors: the proteoglycans. We found that dermatan sulfate was required for ﬁbroblast
migration into a ﬁbronectin/ﬁbrin gel. This conclusion was based on b-xyloside inhibition of glycanation and
speciﬁc glycosaminoglycan degradation. CD44, a cell surface receptor known to bind hyaluronan, not infrequently
exists as a proteoglycan, decorated with various glycosaminoglycan chains including heparan sulfate and
chondroitin sulfate, and as such can bind ﬁbronectin. We found that CD44H, the non-spliced isoform of CD44, was
necessary for ﬁbroblast invasion into ﬁbronectin/ﬁbrin gels. Resting ﬁbroblasts expressed mostly nonglycanated
CD44H core protein, which became glycanated with chondroitin sulfate and dermatan sulfate, but not heparan
sulfate, after a 24 h incubation with platelet-derived growth factor, the stimulus used in the migration assay. These
results demonstrate that dermatan sulfate-CD44H proteoglycan is essential for ﬁbroblast migration into ﬁbrin clots
and that platelet-derived growth factor, the stimulus for migration, induces the production of chondroitin-sulfate-
and dermatan-sulfate-glycanated CD44H.
Key words: CD-44/cell migration/chondroitin sulfate/collagen/fibroblast/glycosaminoglycan/heparan sulfate/
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Fibroblasts are normally quiescent mesenchymal cells,
which are surrounded by collagenous extracellular matrix
(ECM). After tissue injury, however, fibroblasts in proximity
to the wound become activated (McClain et al, 1996).
During the first 3 d postinjury, fibroblasts proliferate in the
peri-wound stroma. On the fourth day, fibroblasts transmi-
grate from the collagen-rich connective tissue into the
wound provisional matrix, composed mainly of fibrin and
fibronectin (FN) (Clark, 1996). In this provisional matrix,
fibrin forms a three-dimensional scaffold whereas FN
provides a conduit for fibroblast migration (Greiling and
Clark, 1997).
The necessity of FN for fibroblast movement across a
collagenfibrin matrix boundary was recently demonstrated
using an in vitro model of cell movement in a discontinuous
three-dimensional tissue construct that simulates early
wound repair (Greiling and Clark, 1997). FN had to be
present in both the collagen gel and the fibrin gel for
migration to proceed. Furthermore, the integrins avb3 and
a5b1 were also required for this cell transmigration.
Integrins comprise a superfamily of heterodimeric, trans-
membrane cell surface receptors, many of which mediate
cell adhesion to ECM proteins (Hynes, 1992). When ligated,
these receptors transmit intercellular signals (Clark and
Brugge, 1995) and physically connect to the cytoskeleton
(Gumbiner, 1996). It is not surprising that they have been
implicated in cell movement (Huttenlocher et al, 1996).
Nevertheless, other cell surface receptors, including trans-
membrane prostaglandins (PG), may be involved in cell
motility (McCarthy et al, 1996).
Structurally, PG consist of a core protein to which linear
glycosaminoglycans (GAG), such as heparan sulfate (HS) or
chondroitin sulfate (CS), are attached via an O-glycosidic
linkage. PG can modulate adhesion by binding ECM
proteins or receptors on other cells (Milstone et al, 1994;
Jackson et al, 1995; Woods et al, 1998). Furthermore, cell
surface PG can collaborate with integrins in activating
intracellular signaling pathways. For example, fibroblasts
plated on FN required both cell surface PG and integrins to
spread fully, forming focal contacts and stress fibers
(Woods et al, 2000). Interestingly, PG binding sites are often
expressed in close proximity to integrin binding domains
within ECM molecules, suggesting that cellular recognition
Abbreviations: CD44H, standard or hematopoietic form of CD44;
CS, chondroitin sulfate; DS, dermatan sulfate; FN, fibronectin;
GAG, glycosaminoglycan; HA, hyaluronan; HS, heparan sulfate;
MESF, molecules of equivalent soluble fluorochrome.
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of the ECM might involve the formation of clusters including
both cell surface PG and integrins (Iida et al, 1996).
CD44 is a widely expressed cell surface adhesion
receptor, which can be glycanated with either CS or HS
(McCarthy et al, 1996). CD44 represents a family of
molecules, all encoded by one gene. Isoform variability is
generated by post-transcriptional RNA splicing. Up to 10
alternative exons (v1–v10) may be inserted into the mRNA
(Brown et al, 1991; Dougherty et al, 1991; He et al, 1992;
Jackson et al, 1992). In addition, the isoforms can undergo
extensive post-translational modifications including N- and
O-linked glycosylation and O-linked glycanation with GAG
such as HS and CS (Brown et al, 1991; Faassen et al, 1992;
1993; Greenfield et al, 1999). The ‘‘standard’’ or ‘‘hemato-
poietic’’ nonglycanated form of CD44 (CD44H), found on
most cell types, has an apparent size of 85k to 95k on gel
electrophoresis, but its amino acid sequence predicts a
polypeptide of less than 40k molecular weight (Borland
et al, 1998). This difference results from extensive glyco-
sylation of its extracellular domain. CD44H lacks all 10
alternative exons but can be glycanated with CS at the first
serine-glycine site in exon 5 of CD44 (Greenfield et al, 1999).
Alternatively spliced isoforms of CD44 are largely restricted
to cells of epithelial origin, but can also occur in cultured
lymphocytes and monocytes spontaneously (Levesque and
Haynes, 1996) or after treatment with mitogenic agents or
cytokines (Koopman et al, 1993; Mackay et al, 1994) and in
cancer cells (Lesley et al, 1997; Goodison and Tarin, 1998).
CD44 is the principal cell surface receptor for hyaluronan
(HA) (Underhill, 1992); however, not all CD44-expressing
cells bind HA. Both glycosylation and glycanation can affect
HA binding (Borland et al, 1998). When glycanated with CS,
CD44 can bind collagen and FN (Culty et al, 1990; Jalkanen
and Jalkanen, 1992).
Several facts suggest that CD44 may play a role in
fibroblast migration in wound healing. CD44 can be a
receptor for FN or HA, components of the provisional matrix
that facilitate cell migration into a wound site (Knox et al,
1986; McCarthy et al, 1986; Turley, 1992; Clark, 1996;
Greiling and Clark, 1997). Increased CD44 expression
occurs in hypertrophic scar fibroblasts compared to normal
dermal fibroblasts (Messadi and Bertolami, 1993). Finally,
Svee et al (1996) showed that human lung fibroblast
invasion into a fibrin gel required a nonglycanated CD44H.
In this study we demonstrated that human dermal fibroblast
transmigration from collagen matrices into fibrin clots
requires cell surface heparan and dermatan sulfate (DS)
proteoglycans. The latter was attributable to a DS-CD44H
that has not been previously characterized. Resting dermal
fibroblasts expressed mostly nonglycanated CD44H. After a
24 h incubation with platelet-derived growth factor (PDGF),
however, a well-known growth factor and chemotactic
factor for fibroblasts in vitro and an important factor for
wound healing in vivo (Heldin and Westermark, 1996),
CD44H became glycanated with DS and CS.
Results
Invasive migration of human dermal ﬁbroblasts requires
GAG The aim of this study was to investigate if proteogly-
can receptors are functionally involved in the transmigration
of normal adult human dermal fibroblasts from a collagen
matrix into a fibrin gel. Therefore we investigated the
requirement of cell surface CS/DS as it has been shown
by several other groups that CS side chains are critical for
adherence of some cells to FN (Faassen et al, 1992;
Jalkanen and Jalkanen, 1992). For this purpose, b-xyloside
was added to the fibrin gel, which, at the chosen
concentration of 1 mM, prevents the addition of CS/DS
GAG chains to proteoglycan core proteins (Schwarz, 1977).
As a negative control, a-xyloside, an inactive homolog of b-
xyloside, was added to the assay. b-Xyloside inhibited
transmigration by about 90% (Fig 1A). The treatment with
a-xyloside did not have any effect on the invasion of
fibroblasts into the fibrin gel. A longer exposure of the cells
to this substance by pretreatment of the contracted collagen
gels for 24 h did not change the results (data not shown).
Invasive migration of dermal ﬁbroblasts requires DS To
confirm the involvement of CS or DS in cell migration, cells
embedded in collagen gel were exposed to chondroitinase
ABC, an enzyme that degrades all forms of CS from the cell
Figure1
Fibroblast transmigration requires a DS proteoglycan. (A) b-Xylo-
side decreased PDGF-induced transmigration from a collagen matrix
into a fibrin gel. The inactive analog a-xyloside did not change the
number of migrated cells. (B) Chondroitinase ABC and chondroitinase
B inhibited PDGF-induced transmigration. Chondroitinase ACII failed to
influence the amount of accumulated cells in the fibrin gel. The data are
shown as mean  SEM and are representative for three independent
experiments.
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surface: chondroitin-4-sulfate and chondroitin-6-sulfate, as
well as DS (Aruffo et al, 1990). The enzyme was also present
during the assay. Transmigration was inhibited by 65%
at 0.1 U per mL (Fig 1B). To determine which specific
galactosaminoglycan was required for transmigration,
chondroitinases ACII and B were added to the assay.
Chondroitinase ACII digests chondroitin-4-sulfate and
chondroitin-6-sulfate, whereas chondroitinase B is specific
for DS. Like chondroitinase ABC chondroitinase B de-
creased the number of transmigrated cells whereas
chondroitinase AC did not influence the migration at all
(Fig 1B). Both enzymes were used at 0.1 U per mL. From
these data we conclude that transmigration of fibroblasts
from a collagen gel into a fibrin gel requires a cell surface
galactosaminoglycan, specifically DS.
The lack of migration in the presence of chondroitinase
was not due to contaminating protease activity as addition
of ovomucoid (10 mg per mL), a broad-spectrum protease
inhibitor, did not change the results (data not shown). None
of the substances used to alter GAG expression, including
b-xyloside, a-xyloside, chondroitinase ABC, chondroitinase
AC, and chondroitinase B, had a toxic effect on the
fibroblasts as judged by the LDH assay (Sigma, St Louis,
MO). The assay was done as suggested by the supplier.
Greater than 95% LDH was retained in fibroblasts after a
24 h incubation at 371C with each test substance.
Invasive migration of dermal ﬁbroblasts requires
CD44 CD44 can be glycanated with galactosaminoglycans
and/or glucosaminoglycans. Therefore, a CD44 proteogly-
can might be required for adult dermal fibroblast migration
through fibrin gels. This possibility was examined by the
addition of antibodies against different CD44 epitopes to
the fibroblast transmigration assay. In Fig 2(A) antibodies
were added to the fibrin gel at a final concentration of 30 mg
per mL. Only monoclonal antibody BU52 did not influence
transmigration compared to control (Co). Monoclonal anti-
body A1G3 enhanced cell movement, whereas BRIC 214,
BRIC 235, Hermes-3, and A3D8 inhibited it. To further study
the stimulatory and inhibitory antibodies, A1G3 and A3D8,
respectively, their effect on migration was observed in the
concentration range 1100 mg per mL. As shown in Fig 2(B),
monoclonal antibody A3D8 inhibited the transmigration in a
dose-dependent manner with an IC50 at about 4 mg per mL,
whereas monoclonal antibody A1G3 increased the invasive
migration of fibroblasts in a dose-dependent manner with
the optimal effect at 30 mg per mL.
A previous report demonstrated that CD44 antibodies
induced fibroblast apoptosis (Henke et al, 1996a). Using a
sensitive assay for DNA fragmentation (Sugano et al, 1999),
only slight apoptosis was observed with monoclonal anti-
body A3D8 (Fig 3), a monoclonal anti-CD44 antibody when
used at concentrations of 10 mg per mL and higher
completely inhibited fibroblast migration through fibrin gels
(Fig 2B). An equal amount of apoptosis was detected with
monoclonal antibody A1G3 (Fig 3), a monoclonal anti-
CD44 antibody when used at concentrations of 10 mg per
mL and higher greatly increased fibroblast migration
through fibrin gels (Fig 2B). Thus monoclonal antibody
A3D8 inhibition of migration could not be attributed to
fibroblast apoptosis.
A1G3 has been reported to induce HA binding of the
epithelial form of CD44 (Liao et al, 1993), a CD44 isoform
that normally does not have this capability (Stamenkovic
et al, 1989; 1991). To exclude a role of HA on the enhanced
migration observed with A1G3 in our assay system,
Streptomyces hyaluronidase (2 U per mL) was added to
the fibrin gel. Such treatment had no effect on the dose–
Figure2
Fibroblast transmigration requires CD44. (A) Antibodies directed
against different epitopes of CD44 have a differential effect on
fibroblast transmigration. The control (Co) had no antibody addition.
(B) Monoclonal antibody A3D8 (open squares) inhibited PDGF-induced
transmigration whereas A1G3 (closed squares) enhanced the number
of migrated cells. (C) Enhancement of PDGF-induced transmigration by
monoclonal antibody A1G3 (open circles) was not influenced by the
presence of hyaluronidase (closed circles). Data are shown as mean
 SEM and are representative of two independent experiments.
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response curve of A1G3 (Fig 2C). To confirm that
hyaluronidase degraded HA deposited in the fibrin gel by
migrating fibroblasts, HA was stained using a biotin-labeled
HA binding fragment (Hendin et al, 1990). For this immuno-
fluorescence experiment cells were visualized with propi-
dium iodide (Fig 4, panels A, B, C). No HA was present in
fibrin gels if no fibroblasts had migrated (Fig 4D). HA was
present, however, in gels through which fibroblasts had
migrated (Fig 4E). Hyaluronidase cleared gels of HA
deposited by migrating fibroblasts (Fig 4F) but did not
affect migration (Figs 2C, 4C).
Human dermal ﬁbroblasts express only CD44H As a first
step toward elucidating which CD44 isoform(s) human
fibroblasts expressed, cells were labeled with antibodies
against four different spliced variants of CD44 (CD44H,
CD44v3, CD44v4/5, and CD44v6) and analyzed by quanti-
tative flow cytometry. Initially fibroblasts and human
keratinocytes as control cells, which are known to express
CD44 spliced variants (Milstone et al, 1994), were cultured
to 80% confluence on tissue culture plastic. As shown in
Fig 5, the CD44H isoform (panel A), but not the spliced
variants (panels BD), was expressed by fibroblasts. In
contrast, keratinocytes did not express the CD44H isoform
(panel E), but rather expressed the spliced variants CD44v3
(panel F) and CD44v6 (panel H). PDGF and three-dimen-
sional collagen matrix can have an enormous effect on ECM
receptor expression (Xu and Clark, 1996). Therefore,
fibroblasts were cultured either on plastic or in collagen
gels in the absence or presence of 30 ng per mL PDGF for
48 h (Table I). Neither PDGF nor collagen matrix induced
fibroblast expression of CD44 variant forms.
To confirm that human adult dermal fibroblasts ex-
pressed only CD44H, we determined the relative molecular
weight of all CD44 moieties present in fibroblasts in the
presence or absence of 30 ng per mL PDGF for 48 h.
Western blots of fibroblast extracts were probed with the
monoclonal antibody BBA10, which recognizes all CD44
isoforms (Fig 6). Some fibroblast monolayers were treated
with 0.2 U per mL chondroitinase ABC prior to extraction
whereas control monolayers were treated with buffer alone.
Cells cultured in the absence of PDGF gave a prominent
CD44 band located at 85k (Fig 6, lane 1) consistent with
CD44H. After incubation with chondroitinase ABC, CD44
from such non-stimulated cells also ran at 85k (Fig 6, lane
2). CD44 from cells incubated with 30 mg per mL PDGF gave
a large smear at and above 85k (Fig 6, lane 3); CD44 from
such cells treated with chondroitinase ABC located in a
discrete band at 85k (Fig 6, lane 4). Thus, human adult
dermal fibroblasts, with or without PDGF stimulation,
expressed only an 85k CD44 core protein, a relative
molecular weight consistent with CD44H.
PDGF induced dermal ﬁbroblasts to express CS-CD44H
and DS-CD44H To determine whether fibroblast CD44H
was glycanated with CS and/or DS, western blots of
extracts from fibroblasts with or without PDGF stimulation
were probed with a mixture of anti-DDi-OS, DDi-4S, and
DDi-6S monoclonal antibodies against chondroitin ‘‘stubs’’
(Fig 7). Without chondroitinase treatment little or no
chondroitin stubs were observed in non-stimulated cells
(Fig 7, lane 1) and some chondroitin stub was observed in
PDGF-stimulated fibroblasts (Fig 7, lane 5). The latter result
may be secondary to incomplete GAG synthesis of CD44H
as it transits through the endoplasmic reticulum. After
treatment with chondroitinase ABC, a faint band at 85k was
Figure 3
DNA fragmentation in fibrin gel. Fibroblasts were incubated with or
without anti-CDE44 antibody (10 mg per mL) or H202 (5 mM) in the
presence or absence of PDGF in fibrin gel for 24 h. DNA was extracted
and analyzed by electrophoresis on a 1.5% gel. DNA was visualized
with ethidium bromide using a ChemiImager 440 imaging system
(Imgen Technologies). The results shown are representative of three
separate experiments performed on separate occasions. C, no
treatment control.
Figure4
Confocal microscope images of fibrin gel migration assays
double-labeled for cells with propidium iodide (A–C) and HA with
HA-binding peptide (D–F). Fibrin gels (Fib) in the absence of PDGF
demonstrated no fibroblast migration (A) and no HA (D). Collagen gels
(Col) are autofluorescing under the filter settings for FITC (D–F).
Fibroblasts are present in fibrin gels (Fib) incubated with PDGF for 24 h
(B). Migrating fibroblasts and the surrounding fibrin gel (Fib) stain
positive for HA (E). (C), (F) PDGF-stimulated cell migration assay in
which fibrin gels were treated with 10 U per mL hyaluronidase.
Migrating cells (C) are not associated with green fluorescence (F). Bar:
10 mm.
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observed from extracts of non-stimulated cells (Fig 7, lane
2). Little or no signal was detected in non-stimulated cell
extracts after treatment with chondroitinase AC or B (Fig 7,
lanes 3 and 4, respectively). In contrast, fibroblasts
stimulated with PDGF showed abundant chondroitin stub
after treatment with chondroitinase ABC (Fig 7, lane 6) and
modest chondroitin stubs after digestion with chondroiti-
nase AC and chondroitinase B (Fig 7, lanes 7 and 8,
respectively). Similar results were obtained when western
blots of fibroblast extracts were probed with R36 polyclonal
Figure 5
Adult human dermal fibroblasts only
express CD44 isoform CD44H. Fluor-
escence-activated cell sorter analysis
showed that fibroblasts expressed
CD44H (A) whereas CD44v3 (B),
CD44v4/5 (C), and CD44v6 (D) expres-
sion was not detectable as the pattern
was the same as second antibody alone
(arrows represent the maximum level of
cell fluorescence in the absence of
primary antibody). Human keratinocytes
were negative for CD44H (E) but ex-
pressed CD44v3 (F) and CD44v6 (H).
Table I. CD44 isoform expression on adult human dermal ﬁbroblasts, determined by ﬂuorescence-activated cell sorter analysis
Fibroblasts in monolayer culturea Fibroblasts embedded in collagen gel
CD44 isoforms 0 ng per mL PDGF 30 ng per mL PDGF 0 ng per mL PDGF 30 ng per mL PDGF
CD44H 79,400 MESF 75,900 MESF 45,350 MESF 42,230 MESF
CD44v3 Undetectable Undetectable Undetectable Undetectable
CD44v4/5 Undetectable Undetectable Undetectable Undetectable
CD44v6 Undetectable Undetectable Undetectable Undetectable
aFibroblasts were cultured on tissue culture plastic or in collagen gels in the absence or presence of 30 ng per mL PDGF-BB for 48 h.
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antibodies against the chondroitin stubs (data not shown).
These data demonstrate that resting human dermal
fibroblasts express mostly nonglycanated CD44H, which
become glycanated with CS and DS chains after incubation
with PDGF.
To confirm that PDGF induced human dermal fibroblasts
to glycanate CD44H with sulfated GAG, cells were
metabolically labeled with 35SO4 in the absence or presence
of PDGF (100 ng per mL) for 48 h. After incubation the cells
were lyzed and CD44 affinity purified on anti-CD44H/protein
G/agarose beads, aliquots of which were differentially
digested with chondroitinase ABC, AC, or B. After hydro-
lysis with NaOH/NaBH4, reaction mixtures were passed
through a G-50 Sephadex column and fractions were
collected and counted. When experiments were done in
1% serum little CD44 labeling activity was detected in the
presence or absence of PDGF (data not shown). When
experiments were performed in the presence of 10%
serum, however, the addition of PDGF substantially in-
creased CD44 glycanation (Fig 8). In the absence of PDGF
Figure 6
Adult dermal fibroblasts express only 85k CD44 core protein
regardless of stimulation with PDGF. The western blot was probed
with monoclonal antibody BBA10 that recognizes all CD44 splice
variants. Some cell monolayers were incubated with PDGF for 48 h
prior to extraction (lanes 3, 4). Some cell monolayers were digested
with chondroitinase ABC immediately before extraction (lanes 2, 4).
Molecular weight markers (205 kDa, 105 kDa, 70 kDa, and 43 kDa) from
the original SDS-PAGE are indicated on the left-hand side of the figure.
Figure 7
CD44H becomes glycanated with CS and DS after fibroblast
exposure to PDGF. Western blots of fibroblast extracts were probed
for CS/DS stubs with a mixture of anti-DDi-OS, DDi-4S, and DDi-6S
monoclonal antibodies. Human adult dermal fibroblasts were incubated
in the absence (lanes 1–4) or presence (lanes 5–8) of 30 ng per mL
PDGF for 48 h. Immediately prior to extraction cells were incubated
with no enzyme (lanes 1, 5), chondroitinase ABC (lanes 2, 6),
chondroitinase AC (lanes 3, 7), or chondroitinase B (lanes 4, 8). All
bands ran at 85k on SDS-PAGE.
Figure8
Column chromatography of metabolically labeled, affinity-purified,
differentially digested CD44 from human adult dermal fibroblasts
demonstrates that CD44H becomes glycanated with galactosami-
noglycans after PDGF stimulation. Cells were metabolically labeled
with 35SO4 in the absence (panels A–D) or presence (panels EH) of
PDGF (100 ng per mL) for 48 h. After the incubation period, affinity-
purified CD44 was incubated with no enzyme (panels A, E),
chondroitinase ABC (panels B, F), chondroitinase AC (panels C, G), or
chondroitinase B (panels D, H). NaOH/NaBH4 hydrolysates of the
differentially digested CD44 moieties were passed through a G-50
Sephadex column and fractions were collected and counted. V0 and Vt
represent column exclusion volume and total volume, respectively.
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little sulfated GAG was detected in fibroblast monolayers
that had not been treated with enzyme (Fig 8A). Sulfated
GAG were excluded from the G-50 Sephadex column (void
volume 7 mL) whereas sulfated monosaccharides were
retained in the column with a peak at 15 mL, the column
total volume (Vt). No sulfated GAG was detectable after
chondroitinase ABC treatment (Fig 8B) and little was
detected when monolayers had been incubated with
chondroitinase AC (Fig 8C) or chondroitinase B (Fig 8D).
Fibroblasts that had been stimulated with PDGF for 48 h
demonstrated a substantial increase in sulfated GAG
synthesis (Fig 8EH). Digestion of stimulated cells with
either chondroitinase AC (Fig 8G) or chondroitinase B (Fig
8H) demonstrated the presence of DS and CS, respectively.
The amount of DS observed after digestion with chondroi-
tinase AC (first peak in Fig 8G) appeared to be about twice
the amount of residual CS seen after chondroitinase B
digestion (first peak in Fig 8H).
Discussion
After substantial tissue injury, the transmigration of fibro-
blasts and blood vessels from peri-wound collagenous
stroma into the wound provisional matrix is the initial step of
granulation tissue formation (McClain et al, 1996). The
global aim of our laboratory is to understand the functional
mechanisms involved in this complex process. The data
presented here demonstrate that PDGF-induced transmi-
gration of human adult dermal fibroblasts from a type 1
collagen matrix into an FN/fibrin provisional matrix is
dependent on a previously uncharacterized CD44 proteo-
glycan, DS-CD44H.
Monoclonal antibody experiments demonstrated that
CD44 was required for fibroblast invasive migration into
FN/fibrin gels. The question arose, however, whether this
was secondary to a direct interaction with FN or an
interaction with HA deposited by fibroblasts as they
migrated. Both BRIC 214 and BRIC 235 completely
inhibited fibroblast invasive migration into FN/fibrin gels.
Importantly, BRIC 235 had been shown to block interactions
with HA (Liao et al, 1995; Bartolazzi et al, 1996).
Furthermore, A1G3, which remarkably enhanced fibroblast
transmigration in our studies, had been shown to enhance
HA binding to CD44H and the epithelial form of CD44, a
CD44 isoform that does not normally bind HA (Liao et al,
1993, 1995).
Thus, some monoclonal antibody data lead to the
consideration that CD44 might be affecting migration
indirectly through HA. The increased migration stimulated
by A1G3, however, was not due to CD44 interaction with HA
as removal of fibroblast-secreted HA with hyaluronidase did
not change the antibody effect on migration. That the
fibroblast migration observed here was HA independent is
further supported by the fact that monoclonal antibody
A3D8, which also enhances HA binding to CD44H (Liao
et al, 1993; 1995), completely inhibited fibroblast invasive
migration into FN/fibrin gels, rather than stimulating it. The
ability of A3D8 to inhibit migration was not secondary to
apoptosis or other cytotoxic effects. In fact, the small
amount of DNA fragmentation and LDH release observed
was the same whether fibroblasts were exposed to A3D8 or
A1G3. A previous study reported that A3D8 could induce
apoptosis of fibroblasts cultured in fibrin gels (Henke et al,
1996a); however, our assay included PDGF, which is known
to protect cells against apoptosis (Romashkova and
Makarov, 1999).
CD44 may be modified with either CS or HS, or both,
depending on the isoform being glycanated. Only isoforms
with v3 can be substituted with HS (Bennett et al, 1995),
presumably because only the v3 insert has a Ser-Gly-Ser-
Gly consensus sequence, the preferential attachment site
for HS. All other GAG attachment sites in CD44 consist of
Ser-Gly residues in an environment preferential for galacto-
saminoglycan substitution. The expression of CD44 iso-
forms can change in response to differentiation and/or
activation (Arch et al, 1992; Koopman et al, 1993). There-
fore, human adult dermal fibroblasts were cultured in the
absence and presence of PDGF for 48 h and subsequently
analyzed for expression of CD44H, CD44v3, CD44v4/5, and
CD44v6. In both conditions the fibroblasts expressed only
CD44H. Keratinocytes, which are known to express CD44
transcripts that include v3 and v6 (Bennett et al, 1995; Bloor
et al, 2001), were used as a positive control. As ECM has an
enormous effect on PDGF induction of fibroblast integrin
receptors (Xu and Clark, 1996), fibroblasts were also
embedded in collagen gels to examine their effect on
CD44 isoform expression. Again only CD44H was ob-
served, even after incubation with PDGF for 48 h.
Treatment of fibroblasts with chondroitinase enzymes,
chondroitinase ABC, chondroitinase ACII, and chondroiti-
nase B, revealed that cell invasion of FN/fibrin was
dependent on DS but not CS. Chondroitinase ABC
degrades all forms of CS and DS and inhibited migration,
whereas chondroitinase ACII cannot degrade iduronate-
containing DS and did not inhibit migration. Conversely,
chondroitinase B degrades DS but not CS chains and did
inhibit migration. Previously, an uncharacterized DS pro-
teoglycan was shown to be important for fibroblast
proliferation (Denholm et al, 2000). In our 24 h assay,
however, migration is independent of proliferation as it is
unaffected by irradiation (Greiling and Clark, 1997).
Previously, Jalkanen and Jalkanen (1992) demonstrated
that CD44H can be substituted with CS chains. In 1996
Ehnis et al demonstrated that a CS/DS form of CD44 is a
receptor for collagen XIV. The evidence for the latter came
from abrogation of binding with chondroitinase ABC, which
digests both CS and DS. The CD44 proteoglycan respon-
sible for collagen XIV binding was not further characterized.
To determine whether the CD44H on fibroblasts was
glycanated, and, if so, to identify the type of GAG, we
utilized the differential substrate specificity of chondroiti-
nase enzymes, together with monoclonal and polyclonal
antibodies, which recognize ‘‘stubs’’ remaining on the core
protein after enzyme treatment. In the absence of PDGF,
human dermal fibroblasts substituted a small amount of
CD44H with galactosaminoglycans, but GAG levels were
too low to discern whether they were CS, DS, or both.
PDGF-treated dermal fibroblasts expressed CD44H sub-
stituted with greatly increased levels of both DS and CS
chains. Although theoretically PDGF could induce CS or DS
glycanation of other proteoglycan core proteins, only one
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protein band was observed on western blot with ‘‘stub’’
antibodies after chondroitinase treatment. Furthermore, the
protein recognized by ‘‘stub’’ antibodies ran at an apparent
molecular weight of 85k consistent with CD44H (Borland et
al, 1998). These data taken together indicate that overall
glycanation of CD44H was upregulated by PDGF and
suggest that a previously uncharacterized DS-CD44H was
expressed after PDGF stimulation and necessary for human
dermal fibroblast invasion of FN/fibrin. To confirm that CD44
was the core protein to which DS and CS were glycanated,
fibroblasts were labeled with 35SO4 in the presence or
absence of PDGF. CD44 was affinity purified from cell
lysates on anti-CD44/protein G/agarose beads and differ-
entially digested with chondroitinase enzymes. In the
presence of PDGF both CS and DS glycanation adducts
to CD44 were found.
Switching of GAG type in response to a single stimulus
such as a growth factor is infrequently encountered, and
suggests that the expression or activity of the 50 epimerase,
which converts the glucuronate to iduronate (and thereby
converts CS to DS), is regulated by PDGF. Previous data
suggest that PDGF promotes GAG chain elongation and/or
sulfation onto biglycan core proteins of lung fibroblasts
(Liu et al, 1998). The reported effects were mediated by
phosphatidyl-inositol-3-kinase, a known transducer of
PDGF-induced cell migration (Higaki et al, 1996).
Although two previous studies demonstrated that CD44
can mediate cell migration into a fibrin gel, substantial
differences exist between the previous findings and the data
presented here. Henke et al (1996b) showed that rabbit
microvascular endothelial cell invasive migration into rabbit
fibrin was dependent on a CS-CD44 proteoglycan. These
cells expressed both CD44H and CD44v3 isoforms. Svee
et al (1996) demonstrated that lung fibroblasts, isolated
from normal individuals and from patients with adult
respiratory distress syndrome, required CD44 for invasion
of fibrin clots. Similar to the findings in our study, lung
fibroblasts expressed only the CD44H isoform (Svee et al,
1996). Also in concordance with our findings, the addition of
hyaluronidase to fibrin gels did not abrogate the invasive
migration of lung fibroblasts (Svee et al, 1996). The human
lung fibroblast CD44H was not glycanated with CS/DS,
however, and the addition of b-xyloside failed to inhibit lung
fibroblast invasive migration into fibrin gels (Svee et al,
1996), in striking contrast to our findings. As nonglycanated
CD44H can bind HA (Lesley et al, 1997; Naot et al, 1997),
but not FN (Jalkanen and Jalkanen, 1992), fibrinogen
(Henke et al, 1996b), or collagen (Faassen et al, 1992), it
is not clear what substance in the fibrin gel was ligated by
the human lung fibroblast CD44H.
In our previous studies human adult dermal fibroblasts
required exogenous FN (Greiling and Clark, 1997). Pre-
sumably the galactosaminoglycan adducts on CD44 are
necessary for interaction with the FN in the fibrin gels.
Jalkanen and Jalkanen (1992) demonstrated that CS
glycanation was required for lymphocyte CD44 binding to
FN. Furthermore, Barkalow and Schwarzbauer (1991; 1994)
identified an arginine pair within heparin-binding site II (Hep
II) of FN that is critical for HS and CS binding. This same
arginine pair is required for fibroblast migration on FN in our
studies (Clark et al, 2003). Henke et al (1996b) demon-
strated that CS-CD44H binds fibrinogen but did not further
analyze the binding site.
Human dermal fibroblast integrins are necessary and
sufficient for direct adhesion to either FN (Gailit et al, 1993;
Gailit and Clark, 1996) or fibrinogen (Gailit et al, 1997).
Furthermore we have shown that human dermal fibroblast
integrins are necessary for invasive migration into an FN/
fibrin gel (Greiling and Clark, 1997). From this study,
however, it is clear that these cells have additional
requirements for invasive migration through an FN/fibrin
gel. Previous investigators have shown that, whereas FN
binding to integrin receptors is enough to support cell
adhesion, FN interaction with integrins is not sufficient for
cell spreading and focal contact formation (Woods and
Couchman, 1998). For these more complicated processes
additional receptors, such as proteoglycans, seem to be
necessary. Melanoma cells required both CS proteoglycans
and integrins for spreading and focal contact formation (Iida
et al, 1995). Furthermore, melanoma cell migration on
collagen required CS-CD44, as well as the collagen
receptor a2b1 integrin, whereas cell adhesion to collagen
occurred independently of CS-CD44 (Faassen et al, 1992;
Knutson et al, 1996). In contrast, the predominately HS
proteoglycan, syndecan-4, enhanced integrin-mediated
focal adhesion formation and transmembrane signaling in
fibroblasts (Woods and Couchman, 1998).
Five years ago we reported that fibroblast transmigration
from a collagen matrix into a fibrin gel requires FN and
depends on both a5b1 and avb3 integrins (Greiling and
Clark, 1997). In a subsequent study, we demonstrated that
human adult dermal fibroblast migration on FN requires
three functional domains and a4b1 integrin, as well as a5b1
and avb3 (Clark et al, 2003). Here we demonstrate that
fibroblasts need proteoglycan receptors, such as DS-
CD44H, in addition to integrins, to invade an FN/fibrin gel.
Furthermore, post-translational modification of the CD44
with DS must be induced by PDGF, a growth factor found in
wounds, for migration to proceed. These data taken
together suggest that fibroblast migration is tightly regu-
lated, probably to prevent mesenchymal cell wandering in
the absence of wounding. Epithelial, endothelial, nerve, and
smooth muscle cells have basement membrane architec-
tural boundaries to prevent cell dispersion. It appears that
‘‘naked’’ mesenchymal cells, such as fibroblasts, have
restraints to migration imposed by stringent receptor and
ECM requirements.
Materials and Methods
Recombinant PDGF-BB was a kind gift from Charles Hart at
ZymoGenetics (Seattle, WA) and its use in our experiment was
given institutional approval. FN and thrombin were generously
provided by Gerard Marx at New York Blood Center (New York, NY).
Bovine serum albumin (BSA, fatty acid free, fraction V) was obtained
from Miles (Kankakee, IL). Tissue culture plastic flasks were from
Costar (Cambridge, MA). Hanks’ balanced salt solution (HBSS),
human G-globulin, p-nitrophenyl-a-D-pyranoside (a-xyloside), p-
nitrophenyl-b-D-pyranoside (b-xyloside), and collagenase (type I,
from Clostridium histolyticum) were purchased from Sigma Chemi-
cals (St Louis, MO). Heparinase I, heparinase III (heparitinase I),
chondroitinase ACII, chondroitinase B, chondroitinase ABC, hyalur-
onidase (hyaluronate lyase from Streptomyces hyalurolyticus), and
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ovomucoid were purchased from Seikagaku America (Ijamsville,
MD). Fluorescein isothiocyanate (FITC) microbead calibration stand-
ards were supplied by Flow Cytometry Standards (San Juan, PR).
Antibodies Anti-CD44 antibodies A1G3 and A3D8 were a kind gift
from Barton Haynes, Duke University Medical Center, Durham, NC
(Liao et al, 1993; Patel et al, 1995; Rivadeneira et al, 1995). The
antihuman CD44 antibodies BRIC 214 and 235 (Antsee et al, 1991)
and Hermes-3 (Jalkanen et al, 1987) were obtained from the Fifth
International Workshop on Leukocyte Differentiation Antigens and
came from the Laboratories of Dr D. J. Antsee, International Blood
Group Reference Laboratory, Bristol, UK, and Dr S. Jalkanen,
Turku University, Finland, respectively. BU52, another anti-CD44
antibody, was purchased from The Binding Site (San Diego, CA).
Monoclonal antibodies against human CD44H, CD44v3, CD44v4/
5, and CD44v6 were obtained from R&D Systems (Minneapolis,
MN). FITC conjugates of goat antimouse IgG was purchased from
Caltag Laboratories (South San Francisco, CA).
Fibrinogen Human fibrinogen containing approximately a 1:10
molar ratio of FN (Greiling and Clark, 1997) was obtained from
Calbiochem (San Diego, CA). To prevent fibrinolysis, plasminogen
was removed from the fibrinogen by passage through a lysine-
Sepharose 4B column (Pharmacia, Piscataway, NJ) (Deutsch and
Mertz, 1970). The clottability before and after treatment with lysine-
Sepharose 4B was over 90%.
Cells Primary cultures of human adult dermal fibroblasts (a kind
gift from Marcia Simon, Living Skin Bank, SUNY at Stony Brook)
were cultured in Dulbecco’s modified Eagle’s medium (DMEM, Life
Technologies, Gaithersburg, MD), containing 42 mM sodium
bicarbonate and supplemented with 100 U per mL penicillin, 100
mg per mL streptomycin, and 10% fetal bovine serum (HyClone,
Logan, Utah), at 371C and 5% CO2/95% air in a humidified
atmosphere. Cells were used between passages 4 and 12.
Normal human keratinocytes were obtained from neonatal
foreskins and grown for two passages with lethally irradiated 3T3-
J2 cells (Rheinwald and Green, 1975) using a modified medium
(Randolph and Simon, 1993). Keratinocyte cultures were char-
acterized and determined to be greater than 99% pure on the basis
of characteristic polygonal morphology and immunofluorescence
detection of keratin-positive cells. For use cells were grown in
serum-free, low-calcium (0.15 mM) medium KGM from Clonetics
(San Diego, CA). Experiments were done using fourth passage
keratinocytes.
Preparation of ﬂoating, contracted collagen gels Fibroblast
cultures at 80% confluence were harvested by treatment with
0.05% trypsin/0.01% ethylenediamine tetraacetic acid (EDTA).
Trypsin was inactivated by addition of soybean trypsin inhibitor in
phosphate-buffered saline (PBS) containing 0.2% BSA. The cells
were washed twice with DMEMþ 2% BSA and resuspended at a
concentration of 1  106 cells per mL. The fibroblasts were mixed
with neutralized collagen (Vitrogen 100, Celtrix Laboratories, Santa
Clara, CA), 2% BSA, 30 ng per mL PDGF-BB, 30 mg per mL FN,
and concentrated DMEM so that the final concentration of DMEM
was 1  . 600 mL of the cell mixture were added to each well of a
24-well tissue culture plate, which was precoated with 2% BSA,
and the collagen was allowed to polymerize at 371C and 5% CO2.
Final concentration of collagen was 1.8 mg per mL and each gel
contained 6  104 cells. After 2 h incubation, the gels were gently
detached from the plastic surface to allow contraction. 30 ng per
mL PDGF-BB in 0.5 mL DMEMþ 2% BSA was added, and gels
were incubated overnight at 371C in 5% CO2/95% air in a
humidified atmosphere.
Preparation of dried ﬁbrin ﬁbrils Fibrinogen was mixed with
concentrated DMEM and 0.5 U per mL thrombin so that the final
concentration of fibrinogen was 300 mg per mL and of 1  DMEM.
Aliquots of 450 mL were added to each well of a 24-well plate, and
after a 2 h incubation at 371C in 5% CO2, polymerized gels were
dried overnight at 251C under sterile conditions.
Preparation of three-dimensional transmigration model Dried
fibrin fibril-coated dishes were washed once with PBS and
contracted collagen gels were placed on the surface. Fibrinogen,
at a final concentration of 300 mg per mL, was mixed with DMEM
and 1.0 U per mL thrombin. When needed, other supplements
such as growth factors were added to the mixture. The collagen
gels were surrounded with the fibrinogen solution so that the fibrin
gel was level with the collagen gel (Greiling and Clark, 1997).
Evaluation The number of migrated cells was evaluated under a
Nikon inverted phase microscope by counting identifiable cell
nuclei located outside the contracted collagen gel within the fibrin
gel. Each condition was run in triplicate and experiments were
repeated at least three times.
Addition of substances to transmigration assay Substances
were generally added directly into the fibrinogen solution before
addition of thrombin. In experiments with enzyme addition or if a
pretreatment with a substance was necessary, the contracted
collagen gels were exposed to the enzyme or the substance in the
appropriate concentration and for the appropriate period of time
before attaching them to the dried matrix. Then, the pretreated
collagen gels were attached to the fibrin fibrils and, additionally, the
enzyme or substance was added at the same concentration to
the fibrin gel. The concentrations and pretreatment times for the
substances are as follows: a- and b-xyloside, 1 mM, 24 h;
heparinase I and III, 0.1 U per mL, 30 min; chondroitinases AC, B,
and ABC, 0.1 U per mL, 30 min.
HA staining In some cell migration assays fibrin gels were treated
with 10 U per mL hyaluronidase to clear any HA from the gel that
might have been deposited during fibroblast migration. To
determine whether any HA was present in gels not treated with
hyaluronidase and, if present, whether hyaluronidase had effec-
tively cleared the gels of HA, fibrin gels were stained for HA using a
biotin-labeled HA binding fragment (Calbiochem) (Hendin et al,
1990). In preparation for this staining, gels were rinsed with PBS
three times followed by fixation with 3% paraformaldehyde at 251C
for 25 min and another three washes with PBS. Gels were blocked
with 2% BSA in PBS for 2 h and then cells were stained with 20 mg
per mL propidium iodide for 2 h at room temperature. After
washing with PBS, gels were incubated with biotin-labeled HA
binding fragment at 41C for 48 h. After another wash with PBS, the
gels were incubated with Oregon Green 488 conjugated strepta-
vidin at 41C for 30 min. Unbound streptavidin conjugate was
washed away with PBS. Stained specimens were observed and
images were captured using a Leica SP2 confocal microscope
equipped with a halogen light source and a CCD camera.
DNA fragmentation analysis To identify DNA fragments after
exposure to anti-CD44 antibodies in fibrin gel, two protocols were
used, those of Henke et al (1996a) and Sugano et al (1999). Even in
the presence of H2O2 the primary dermal fibroblasts that we used
failed to show any DNA fragmentation with the Henke method,
whereas some fragmentation was noted with the Sugano method.
Thus, for the data in this report we used the Sugano method.
Briefly, fibroblasts in fibrin gels (300 mg per mL) were incubated
with 30 ng per mL PDGF with or without 10 mg per mL anti-CD44
antibody or 5 mM H2O2 for 24 h at 371C. Gels were digested with
trypsin/EDTA at 371C, followed by washing to remove fibrin. Cells
were then treated with 30 mL of lysis buffer (10 mM TrisHCl, 10
mM EDTA, 2% Triton-X 100, pH 8.0) for 10 min at 41C. After
centrifugation at 469 g for 20 min, the supernatant was collected
and treated for 1 h with RNAse A (0.4 mg per mol) at 371C followed
by digestion with proteinase K (0.4 mg per mL). The DNA was
separated by electrophoresis on 1.5% agarose gel containing
ethidium bromide, visualized, and photographed with a ChemiI-
mager 4400 system.
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Quantitative ﬂow cytometry Fibroblasts and keratinocytes were
cultured to 70%–80% confluence. For studies done in monolayer
cultures, medium was removed at the beginning of treatment and
cells were washed three times with PBS. Fibroblasts were then
exposed either to DMEMþ 2% BSA or to DMEMþ 2% BSAþ 30
ng per mL PDGF, whereas keratinocytes were cultured in
KGMþ 2% BSA  30 ng per mL PDGF. After 48 h the cells were
assayed for CD44 isoform expression by quantitative flow
cytometry essentially as previously described (Gailit and Clark,
1996).
In addition, fibroblasts were embedded in collagen gelsþ 2%
BSA and 30 ng per mL PDGF as was done for the transmigration
assay. Then, the contracted collagen gels were incubated with
DMEMþ 2% BSA or with DMEMþ 2% BSA and 30 ng per mL
PDGF. After 48 h at 371C and 5% CO2/95% air in a humidified
atmosphere the gels were digested by incubation with 1 mg per mL
collagenase for 1 h in a shaking waterbath. After centrifugation and
resuspension in PBS the cells were assayed for CD44 isoform
expression.
In both situations resuspended cells were mixed 4:1 (final cell
concentration 1  106 cells per mL) with a blocking solution
containing 10 mg per mL human g-globulin and 0.2% sodium azide
in HBSS. After incubation for 10 min on ice, 4  105 cells were
transferred to tubes and washed twice with FC medium. The cells
were then resuspended in 100 mL of primary antibody diluted in FC
medium (1:1000 each) and incubated for 60 min on ice. Then, cells
were washed twice with 2 mL cold FC medium (hanks with 0.2%
BSA and 0.2% oxide). They were resuspended in 50 mL of
secondary antibody diluted in FC medium (FITC conjugates of goat
antimouse, diluted 1:50), mixed gently, and incubated for 30 min on
ice. The cells were washed once with 2 mL cold FC medium and
then fixed for 20 min on ice with 0.5 mL of PBS containing 1%
paraformaldehyde. After fixation, 2 mL cold PBS containing 0.2%
sodium azide was added to each tube. The tubes were centrifuged
to pellet the cells and the cells were resuspended in 0.5 mL cold
PBS containing 0.2% sodium azide.
Cell surface expression of CD44 isoforms was analyzed by
quantitative flow cytometry performed with a FACStar Plus cell
sorter (Becton Dickinson Immunocytometry Systems, San Jose,
CA) running LYSYS II software. Samples were gated by forward
and side scatter to exclude cell aggregates and cell debris. FITC
microbead standards allow for the conversion of relative fluores-
cence intensity into an absolute value, the number of molecules
of equivalent soluble fluorochrome (MESF). The results reported
here are based upon the calculated MESF value for each ex-
perimental sample minus the MESF value for the appropriate
antibody control.
Western blot of proteoglycans This procedure was done with
slight modification as described earlier (Couchman et al, 1996).
Briefly, fibroblasts were washed in serum-free medium and then
incubated for 45 min at 371C in HBSS lacking phosphate but
buffered with 30 mM sodium acetate at pH 7.4. Some cultures
were treated with chondroitinase ABC or ACII in this buffer (0.2 U
per mL), whereas others were treated with 0.1 mL chondroitinase B.
After this treatment monolayers were lyzed directly in 100 mL of
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) sample buffer containing 20 mM dithiothreitol, before
heating at 1001C for 3 min. Samples were run on 4%–15% SDS-
PAGE and transblotted to nitrocellulose as previously described.
The blots were blocked and processed as described (Couchman et
al, 1996). Blots were probed with an antibody against CD44H (R&D
Systems, 2 mg per mL), R36, polyclonal antibodies raised against
chondroitinase ABC digested aggrecan from bovine nasal cartilage
(Couchman et al, 1996), or with a mixture of 5 mg per mL each
of anti-DDi-OS, DDi-4S, and DDi-6S monoclonal antibodies
(Seihaguku America) (Couchman et al, 1984). R36 and the mixture
of monoclonal antibodies recognize chondroitin/dermatan ‘‘stubs’’
generated by chondroitinase treatment. Secondary antibodies
were goat antimouse IgG or goat antirabbit IgG coupled
to horseradish peroxidase (Bio-Rad, Hercules, CA dilutions
1:3000). The presence of peroxidase was determined by chemi-
luminescence (Amersham).
Sulfated GAG synthesis Fibroblasts were cultured with 35SO4 (50
mCi per mL) for 48 h at 371C in DMEM containing 10% fetal bovine
serum in the absence or presence of PDGF (100 ng per mL). After
washing with cold PBS, the cells were dissolved in immunopre-
cipitation buffer (50 mM TrisHCl, pH 7.5, 50 mM NaCl, 0.75 mM
CaCl2, 1% Triton X-100, and protease inhibitors). Lysates were
spun down and supernatants were incubated with protein-G-
conjugated agarose beads for 90 min at 41C to remove non-
specific binding. After centrifugation, supernatants were incubated
with anti-CD44H antibody, which had been linked to protein G/
agarose beads, for 90 min at 41C. After washing thoroughly, the
beads were digested with chondroitinase ABC, AC, or B (0.2 U per
mL) for 24 h at 37 1C, followed by digestion with NaOH/NaBH4 for
24 h at 371C. Reaction mixtures were adjusted to pH 7.4 with HCl
and passed through a G-50 Sephadex column, eluted with 0.5 M
NaCl, 20 mM TrisHCl, pH 7.4, and 0.1% Triton X-100. Fractions
were collected and counted with a liquid scintillation counter.
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